<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.82042</article-id><article-id pub-id-type="publisher-id">ACM-24597</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180200000_38777178.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肿瘤相关内皮祖细胞生物学性状分析、比较
  Analysis and Comparison of Biological Characteristics of Tumor Related Endothelial Progenitor Cells
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>堃</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>程</surname><given-names>玮</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>心</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>志亮</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>纪</surname><given-names>宗正</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黎</surname><given-names>一鸣</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曹</surname><given-names>罡</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>段</surname><given-names>艳霞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>西安市儿童医院呼吸内科，陕西 西安</addr-line></aff><aff id="aff1"><addr-line>西安交通大学医学院第二附属医院普通外科，陕西 西安</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>topestyk@163.com(闫堃)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>03</month><year>2018</year></pub-date><volume>08</volume><issue>02</issue><fpage>247</fpage><lpage>252</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：以正常人为对照探讨内皮祖细胞在肝癌患者中组织学分布的差异性、分析其表面标志物表达情况、细胞形态变化、增殖和管形成能力改变。方法：密度梯度离心、免疫磁珠贯序分离获取单个核细胞，用条件分化培养基进行分化刺激培养，直到分化成熟为内皮细胞。流式检测其生物标志物变化情况。分化潜能，倍增能力，功能状况。结果：单个核细胞经条件诱导培养可定向分化为内皮祖细胞，表现出部分血管内皮的功能特征。肝癌患者骨髓、外周血与正常人无差异，脾内内皮祖细胞系分化明显增强。结论：来源于骨髓单个核细胞分布于多个组织中，可定向分化为内皮祖细胞，进而成熟为内皮细胞，此过程干/祖细胞的生物学特征逐渐降低直至消失。肝癌患者脾脏为此过程提供了最佳的分化诱导内环境。 Objective: Our study aims to assess the difference of endothelial progenitor cells (EPC) between normal controls and liver cancer patients, and to explore the sources, distribution, tube formation ability and biomarker of EPC. Methods: The mononuclear cells were separated by density gradient centrifugation bind with immune magnetic beads. They could develop into the endothelial cells with conditions medium stimulate regeneration. Flow cytometer technology detected the surface antigen changes of all process. Results: The mononuclear cells could induce to develop into the EPC. There is no difference between the liver cancer patients and normal controls in bone marrow and peripheral blood. But the endothelial progenitor cells from the spleen are obviously increased in the liver cancer patients. Conclusion: The mononuclear cells, which derived from bone marrow and distributed in all organization, could develop into EPC and the endothelial cells. The biological characters of progenitor cells reduced gradually during this process. The microenvironment of spleen in liver cancer patients are the favorable to the differentiation of mononuclear cells. 
  
 
</p></abstract><kwd-group><kwd>血管生成，内皮祖细胞，生物学性状，肝癌，脾脏, Angiogenesis</kwd><kwd> Endothelial Progenitor Cells</kwd><kwd> Biological Characteristics</kwd><kwd> Liver Cancer</kwd><kwd> Spleen</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肿瘤相关内皮祖细胞生物学性状分析、比较<sup> </sup></title><p>闫堃<sup>1*</sup>，程玮<sup>2</sup>，徐 心<sup>1</sup>，王志亮<sup>1</sup>，李杰<sup>1</sup>，纪宗正<sup>1</sup>，黎一鸣<sup>1</sup>，吴涛<sup>1</sup>，曹罡<sup>1</sup>， 段艳霞<sup>1</sup></p><p><sup>1</sup>西安交通大学医学院第二附属医院普通外科，陕西 西安</p><p><sup>2</sup>西安市儿童医院呼吸内科，陕西 西安</p><disp-formula id="hanspub.24597-formula84"><graphic xlink:href="//html.hanspub.org/file/26-1570482x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年3月28日；录用日期：2018年4月20日；发布日期：2018年4月27日</p><disp-formula id="hanspub.24597-formula85"><graphic xlink:href="//html.hanspub.org/file/26-1570482x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：以正常人为对照探讨内皮祖细胞在肝癌患者中组织学分布的差异性、分析其表面标志物表达情况、细胞形态变化、增殖和管形成能力改变。方法：密度梯度离心、免疫磁珠贯序分离获取单个核细胞，用条件分化培养基进行分化刺激培养，直到分化成熟为内皮细胞。流式检测其生物标志物变化情况。分化潜能，倍增能力，功能状况。结果：单个核细胞经条件诱导培养可定向分化为内皮祖细胞，表现出部分血管内皮的功能特征。肝癌患者骨髓、外周血与正常人无差异，脾内内皮祖细胞系分化明显增强。结论：来源于骨髓单个核细胞分布于多个组织中，可定向分化为内皮祖细胞，进而成熟为内皮细胞，此过程干/祖细胞的生物学特征逐渐降低直至消失。肝癌患者脾脏为此过程提供了最佳的分化诱导内环境。</p><p>关键词 :血管生成，内皮祖细胞，生物学性状，肝癌，脾脏</p><disp-formula id="hanspub.24597-formula86"><graphic xlink:href="//html.hanspub.org/file/26-1570482x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/26-1570482x8_hanspub.png" /> <img src="//html.hanspub.org/file/26-1570482x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>从组织胚胎学角度，内皮祖细胞(endothelial progenitor cells, EPCs)生长发育的起源头于胚胎期的多能干细胞及骨髓内多能造血干细胞。在特定的条件下，如胚胎发育等生理过程和炎症、肿瘤等病理过程，其受信号传导调节后释放进入循环，在外周组织中特定的微环境内增殖、分化后定向归巢参与血管新生。内皮祖细胞的发现改变了早期认为Angiogenesis [<xref ref-type="bibr" rid="hanspub.24597-ref1">1</xref>] 的芽生方式是成熟个体血管形成的唯一形式。1971年美国哈佛大学医学院Judah Folkman教授据此提出了肿瘤相关血管理论 [<xref ref-type="bibr" rid="hanspub.24597-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.24597-ref3">3</xref>] ，当时认为Vasculogenesis即内皮祖细胞仅参与个体发育早期阶段的，但最近研究却发现，EPCs在冠心病、哮喘等血管重构性疾病及肿瘤、组织损伤再生都发挥着重要的作用 [<xref ref-type="bibr" rid="hanspub.24597-ref4">4</xref>] 。内皮祖细胞的标志、分类、分化的信号通路尚未统一，我们对人源EPCs进行分离比对，初步观察不同组织来源的EPCs的生物学表形差异。</p></sec><sec id="s4"><title>2. 材料和方法</title><sec id="s4_1"><title>2.1. 材料</title><p>20份外周血(取自15份肝癌患者及5份正常查体志愿者)，10份骨髓标本(取自3份肝癌患者及7份正常志愿者)，5份脾脏标本(1份肝癌患者及4份外伤脾破裂患者)，6份脐带血及12份脐带(取自健康足月顺产或剖宫产的新生儿)。M-199培养液，无血清生长因子复合物，Ab-CD34(小鼠源)，同型IgG (Abnova)，SP免疫组化试剂，DAB显色试剂盒 (福州迈新)；磁珠分离套装盒(NEB)，倒置光学显微镜； 37 ℃ 孵箱(Forma Scientific)；Coulter流式细胞仪(Beckman)；留取外周静脉：留取20 mL新鲜外周血，5%肝素抗凝。采集后2 h内进行分离。胎盘娩出后脐血立即于CPDA 抗凝的采血袋内保存。脐带血采集后在无菌条件下离心(4℃ 800 r/min &#215; 10 min)，接种于含2%LSGS(低血清补充物)的M199培养基，静置于37℃ 5% CO<sub>2</sub>孵箱中培养4~12 h。从髂后上棘留取骨髓，收集于肝素抗凝剂的10 mL离心管中。采集后2 h内进行分离。本研究经西安交通大学第二附属医院伦理委员会批准并经患者知情同意。</p><p>外伤脾脏破裂急诊手术取脾后，立刻取新鲜脾脏组织，研磨后以Percoll液(1.082 g/L)重悬， 4 ℃ 离心(2 000 r/min &#215; 20 min)。离心后留取中间云雾层细胞，用M-199接种培养。</p></sec><sec id="s4_2"><title>2.2. 方法</title></sec><sec id="s4_3"><title>2.2.1. 细胞分离培养</title><p>首先，应用密度梯度离心获得单个核细胞后采用免疫磁珠分选CD133+细胞(具体操作依据NEB磁珠分选试剂盒略作修改)，获得的细胞重悬于无血清含细胞生长因子复合物的M-199培养基中，以1 &#215; 10<sup>6</sup>/cm<sup>3</sup>接种于T25培养瓶(均预先用5 &#181;g/cm<sup>2</sup> Fibronectin于37℃包被3 h)中，静置48小时后隔日半量更换无血清培养液，计为P0代细胞，计算平均贴壁细胞数。每3日计数集落数。达70%~80%时传代，以(1~5) &#215; 10<sup>3</sup>/cm<sup>2</sup>接种培养。</p><sec id="s4_3_1"><title>2.2.2. 细胞鉴定</title><p>隔日不同放大倍数下倒置显微镜观察细胞，记录形态特征。对数生长期细胞传代后消化离心，调整细胞密度为1 &#215; 10<sup>7</sup>/L，PBS重悬。每份细胞悬液取200 μL，分别加入荧光标记的CD34、CD133、CD31、VEGFR2和CD14单抗各20 μL，4℃避光共孵育3小时，PBS洗涤2次后测定，流式复测3次取均值。</p></sec><sec id="s4_3_2"><title>2.2.3. 细胞增殖、分化潜能测定</title><p>分离获得的EPC编号并记录来源信息后，自P0代EPC开始至细胞生长至80%开始传代，直至细胞衰老。细胞计数，绘制时间–细胞增殖曲线。</p><p>每组设复孔5个，分别于传代后24 h、48 h、72 h测定细胞的增殖情况：按照MTT试验的常规方法加入MTT溶液，继续培养4 h，弃上清，再加入DMSO，振荡10 min使结晶充分溶解，在光密度测定仪上490 nm处测OD值。以均数 &#177; 标准差(Mean &#177; SD)表示。</p><p>EPC稳定传代后，消化离心并计数。计算消化率 = (该时间被消化下的细胞数/该培养单元的细胞总数) &#215; 100%，做出消化率–时间曲线，以此间接反映细胞粘附力的变化；</p></sec><sec id="s4_3_3"><title>2.2.4. 管形成能力测定</title><p>0℃条件下，Matrigel包被96孔板，37℃凝固，30 min后接种5 &#215; 10<sup>4</sup>/ml对数生长期的细胞，每孔100 μl，约5000个细胞，于 37 ℃ 、5%CO<sub>2</sub>绝对静置48 h。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. EPC分离、鉴定</title><p>采用磁珠吸附及梯度离心贯序分离获得的EPC立刻接种，绝对静置6~12 h开始贴壁，细胞极性不显著，呈团状聚集，多边形，24 h后铺路石交错排列，单层贴壁生长、核质分解清晰，胞核呈类圆形。48 h铺满整个瓶皿后传代培养，内皮细胞在2~3 h后逐渐贴壁，呈多角形、长多角形或梭形，细胞间相互连接，较第一代细胞生长旺盛，肝癌患者脾分离的EPC可见多核及巨细胞(见图1)。可正常传7~8代，此后，细胞增殖力下降、数目减少、逐渐变性变形，呈条索状或网格状，不能形成单层、不能继续传代培养。</p><p>图1. EPC体外培养细胞形态&#215;100</p><p>健康人群骨髓、脐血、脾脏、外周血所获得的EPC数量之比约为15:10:10:1，这与陆士新教授的结果相似 [<xref ref-type="bibr" rid="hanspub.24597-ref5">5</xref>] 。肝癌患者骨髓、脾脏、外周血之比为5:4:1，健康人与肝癌患者骨髓所获得EPC大致相同，我们未观察到单一的肝癌患者出现骨髓动员的现象。</p><p>EPCs生物表型变化随代次增加，干/祖细胞的表面标志物数量急剧降低，功能标志物增高，但无明显组间差异。分化表型标志物CD133，CD31，VEGFR2至第10代达到平台期。</p><p>EPCs增殖潜能的变化接种成功的EPC，经短暂的休眠期后，即进入对数增殖阶段体外培养约每72 h可传一代，第4~6代达增殖峰期，第9~10代急剧下降，细胞呈纤维细胞样改变，传代难以成活。</p></sec><sec id="s5_2"><title>3.2. 管形成实验</title><p>在Matrigel中EPC初始形成类圆形结构，后逐渐伸展呈梭状，接着形成管状结构内皮性结构。倒置显微镜下观察，可见种植于Matrigel中的培养细胞逐渐延伸变长、首尾相接、呈树枝状或网状，形成典型的管状结构(见图2)。这就证实了EPC具有分化成熟为功能性内皮细胞的特性。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>目前的研究认为，成熟个体血管形成主要有两种形式，即血管发生(vasculogenesis)和血管生成(angiogenesis)。传统认为vasculogenesis不依赖于已有的成熟的脉管系统，由干细胞增殖分化而来，经塑形、管化、再通等过程形成血管，多见于胚胎早期阶段 [<xref ref-type="bibr" rid="hanspub.24597-ref6">6</xref>] 。而angiogenesis以芽生方式来源于已有的成熟的血管系统，一度被认为是成体血管形成的主要形式。血管发生是一种普遍存在的生理、病理现象，可见于生命的各个阶段，如外伤修复，月经周期子宫内膜功能性改变，肿瘤等病理生理过程 [<xref ref-type="bibr" rid="hanspub.24597-ref7">7</xref>] 。</p><p>单个核细胞的体外成功分离见于30年前，体外分离获得EPC可分为早期和晚期克隆。Asahara [<xref ref-type="bibr" rid="hanspub.24597-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.24597-ref9">9</xref>] 1997年首先使用免疫磁珠方法从人的外周血单个核细胞中培养分离出血管内皮标记物CD34(+)EPC。给予粒细胞–集落刺激因子(G-CSF)刺激下，CD34(+)EPC随即分化，呈现管内皮特征 [<xref ref-type="bibr" rid="hanspub.24597-ref10">10</xref>] 。伴随细胞归巢过程，趋化迁移受体表达的上调，细胞呈现明显定向分化表现。我们分离的CD34(+)EPC细胞，随着诱导培养代次增加，VEGFR-2(+)表达上调，此外还表达SDF-1、CXCR4、钙粘连素、选择素等内皮生物特异性标志物，并通过旁分泌或自分泌形式在上述因子作用下发生归巢现象。Harraz [<xref ref-type="bibr" rid="hanspub.24597-ref11">11</xref>] 等认为CD14(+)也为EPC特异性表面标志物之一，但我们实验在不同代次细胞间未发现其发生明显特异性变化，这可能与EPC这一异质性较强的细胞不同细胞亚群有关。</p><p>内皮祖细胞根据其增殖分化潜能不同有两种主要类型的，即早内皮祖细胞和晚内皮祖细胞 [<xref ref-type="bibr" rid="hanspub.24597-ref12">12</xref>] ，其中，</p><p>图2. Matrigel胶管形成试验&#215;100</p><p>前者是分化早期的，增殖能力较强的细胞，其特异性表型为CD34+ VEGFR2+ CD133+，后者分化中后期，接近功能细胞的群体，标志物为CD34+ VEGFR2+CD133−。</p><p>此外，Yoder等 [<xref ref-type="bibr" rid="hanspub.24597-ref13">13</xref>] 研究表明，单个核细胞仍具有多分化潜能，例如某些单个核细胞可经诱导分化为单核–巨噬细胞系，因而不能将单个核细胞等同于EPC。</p><p>脾脏是重要的髓外造血器官，传统上认为出生后，其造血功能逐渐退化。演变为一个周围免疫器官。李宗芳教授 [<xref ref-type="bibr" rid="hanspub.24597-ref14">14</xref>] 经过多年的研究发现脾脏有着独特的血液循环方式，其微环境在血细胞的分化、成熟、归巢中起着重要的作用。同时，还发现脾脏在肝癌的病情演变中呈现双向调节性，其具体机制尚未探明。单个核细胞的分化微环境的变动可使分化方向由单核-巨噬细胞系方向转为内皮细胞系方向，这极有可能是一个重要的“Switch”。</p><p>1971年Judah Folkman教授 [<xref ref-type="bibr" rid="hanspub.24597-ref15">15</xref>] 提出肿瘤血管靶向治疗理论后，开创了肿瘤靶向治疗的新纪元，建立了肿瘤治疗的新策略。相继有GX1、DKK1等多肽为代表的肿瘤血管靶向标志物得到研发。我们也曾参与胃癌血管靶标GX1的筛选。Bevacizumab (Avastin)是首个被FDA批准使用于临床的肿瘤血管靶向药物，但经一段时间的应用，发现Bevacizumab并不能获得理论上的疗效，患者的生存期仅能延长数月，死亡率无改善，并且很快出现理论无法解释的耐药问题。这也使Bevacizumab (Avastin)成为目前唯一一个被FDA批准使用于临床的肿瘤血管 [<xref ref-type="bibr" rid="hanspub.24597-ref16">16</xref>] 靶向药物。因此，我们从新审视肿瘤血管形成理论，显然angiogenesis不是肿瘤血管形成的唯一方式。Vasculogenesis被视为完善肿瘤血管形成机制的重要组成部分，EPC作为vasculogenesis的中心环节，对整个通路的研究起着重要的作用。我们分离获得EPC一方面旨在为肿瘤相关血管理论奠定试验基础，同时希望我们的研究能够丰富这一理论，使其重焕光彩。</p></sec><sec id="s7"><title>基金项目</title><p>本实验接受陕西省科学技术研究发展计划项目资助(项目编号：2011K 13-03-11 )。</p></sec><sec id="s8"><title>文章引用</title><p>闫 堃,程 玮,徐 心,王志亮,李 杰,纪宗正,黎一鸣,吴 涛,曹 罡,段艳霞. 肿瘤相关内皮祖细胞生物学性状分析、比较 Analysis and Comparison of Biological Characteristics of Tumor Related Endothelial Progenitor Cells[J]. 临床医学进展, 2018, 08(02): 247-252. https://doi.org/10.12677/ACM.2018.82042</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24597-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bilusic, M. and Wong, Y.N. (2014) Anti-Angiogenesis in Prostate Cancer: Knocked Down but Not Out. Asian Journal of Andrology, 16, 372-377. https://doi.org/10.4103/1008-682X.125903</mixed-citation></ref><ref id="hanspub.24597-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bielenberg, D.R. and Zetter, B.R. (2015) The Contribution of Angiogenesis to the Process of Metastasis. Cancer Journal, 21, 267-273. https://doi.org/10.1097/PPO.0000000000000138</mixed-citation></ref><ref id="hanspub.24597-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bertz, S., et al. (2014) Increased Angiogenesis and FGFR Protein Ex-pression Indicate a Favourable Prognosis in Bladder Cancer. Virchows Archv, 465, 687-695. https://doi.org/10.1007/s00428-014-1672-9</mixed-citation></ref><ref id="hanspub.24597-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Berretta, M., et al. (2016) Angiogenesis Inhibitors for the Treatment of Hepa-tocellular Carcinoma. Frontiers in Pharmacology, 7, 428. https://doi.org/10.3389/fphar.2016.00428</mixed-citation></ref><ref id="hanspub.24597-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yu, P., et al. (2016) Progesterone Modulates Endothelial Progenitor Cell (EPC) Viability through the CXCL12/ CXCR4/PI3K/Akt Signalling Pathway. Cell Proliferation, 49, 48-57. https://doi.org/10.1111/cpr.12231</mixed-citation></ref><ref id="hanspub.24597-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Baharara, J., et al. (2014) Anti-Angiogenesis Effect of Biogenic Silver Nanoparticles Synthesized Using Saliva officinalis on Chick Chorioalantoic Membrane (CAM). Molecules, 19, 13498-13508.  
https://doi.org/10.3390/molecules190913498</mixed-citation></ref><ref id="hanspub.24597-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Salajegheh, A. (2016) Angiogenesis in Health, Diseases and Malignancy. Springer International Publishing Switzerland. Anticancer Research, 36, 3226. https://www.ncbi.nlm.nih.gov/pubmed/27272869</mixed-citation></ref><ref id="hanspub.24597-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ziebart, T., et al. (2016) Significance of Endothelial Progenitor Cells (EPC) for Tumorigenesis of Head and Neck Squamous Cell Carcinoma (HNSCC): Possible Marker of Tumor Progression and Neo-vascularization? Clinical Oral Investigations, 20, 2293-2300. https://doi.org/10.1007/s00784-016-1785-4</mixed-citation></ref><ref id="hanspub.24597-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Falay, M. and Aktas, S. (2016) Endothelial Progenitor Cells (EPC) Count by Multicolor Flow Cytometry in Healthy Individuals and Diabetes Mellitus (DM) Patients. Clinical Laboratory, 62, 2161-2166.  
https://doi.org/10.7754/Clin.Lab.2016.160402</mixed-citation></ref><ref id="hanspub.24597-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Paynter, R., et al. (2017) Commentary on EPC Methods: An Exploration of the Use of Text-Mining Software in Systematic Reviews. Journal of Clinical Epidemiology, 84, 33-36. https://doi.org/10.1016/j.jclinepi.2016.11.019</mixed-citation></ref><ref id="hanspub.24597-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Altabas, V., Altabas, K. and Kirigin, L. (2016) Endothelial Progenitor Cells (EPCs) in Ageing and Age-Related Diseases: How Currently Available Treatment Modalities Affect EPC Biology, Atherosclerosis, and Cardiovascular Outcomes. Mechanisms of Ageing and Development, 159, 49-62. https://doi.org/10.1016/j.mad.2016.02.009</mixed-citation></ref><ref id="hanspub.24597-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wojakowski, W., et al. (2013) Circulating Endothelial Progenitor Cells Are Inversely Correlated with In-Stent Restenosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Treated with EPC-Capture Stents (JACK-EPC Trial). Minerva Cardioangiologica, 61, 301-311.</mixed-citation></ref><ref id="hanspub.24597-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Povsic, T.J., et al. (2013) EPC Mobilization after Erythropoietin Treatment in Acute ST-Elevation Myocardial Infarction: the REVEAL EPC Substudy. Journal of Thrombosis and Thrombolysis, 36, 375-383.  
https://doi.org/10.1007/s11239-013-0944-6</mixed-citation></ref><ref id="hanspub.24597-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yongxiang, W., et al. (2002) Effects of Splenomegaly and Splenic Macrophage Activity in Hypersplenism Due to Cirrhosis. The American Journal of Medicine, 113, 428-431. https://doi.org/10.1016/S0002-9343(02)01210-X</mixed-citation></ref><ref id="hanspub.24597-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Folkman, J., et al. (1971) Isolation of a Tumor Factor Responsible for Angiogenesis. Journal of Experimental Medicine, 133, 275-288. https://doi.org/10.1084/jem.133.2.275</mixed-citation></ref><ref id="hanspub.24597-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, K.A., et al. (2016) Twelve Recommendations for Integrating Existing Systematic Reviews into New Reviews: EPC Guidance. Journal of Clinical Epidemiology, 70, 38-44. https://doi.org/10.1016/j.jclinepi.2015.05.035</mixed-citation></ref></ref-list></back></article>